Sleep Apnea (Obstructive and Central)

Understand

Overview

Sleep apnea is an umbrella term for sleep-breathing disorders involving repeated episodes of complete airflow cessation (apnea) or substantial reduction (hypopnea), typically lasting at least 10 seconds and recurring many times each hour of sleep. Clinically, the same symptom arises from two fundamentally different mechanisms: obstructive sleep apnea (OSA), where the airway physically collapses despite ongoing respiratory effort, and central sleep apnea (CSA), where the airway stays open but the brain temporarily stops sending the signal to breathe. A mixed form combining features of both also exists. This distinction isn't an academic nuance — it determines entirely different diagnostic workups and treatments, and confusing one for the other leads to ineffective therapy.

The clinical significance of sleep apnea goes beyond sleep quality alone, though fragmented sleep architecture and chronic sleep loss carry serious consequences on their own. Each episode ends in a micro-arousal and a sharp surge in sympathetic nervous system activity, and the accompanying periodic drops in blood oxygen (intermittent hypoxia) trigger a cascade of inflammatory and oxidative processes that burden the cardiovascular system. That's why untreated moderate-to-severe sleep apnea is associated in population studies with elevated risk of hypertension, atrial fibrillation, stroke, heart failure, and insulin resistance — it isn't merely a "snoring problem," but a cardiometabolic risk factor with measurable consequences.

The scale of the problem is far larger than commonly assumed. According to a 2019 literature-based analysis by Benjafield and colleagues, drawing on data from more than a dozen countries extrapolated to the global population, nearly a billion adults aged 30-69 worldwide have obstructive sleep apnea of some severity, with a substantial share having a moderate-to-severe form requiring treatment. Central sleep apnea is far rarer and, in the vast majority of cases, secondary to another condition — most often heart failure, a history of stroke, chronic opioid use, or high altitude. Key OSA risk factors include overweight and obesity (especially visceral and peripharyngeal fat), male sex, middle and older age, craniofacial abnormalities (a recessed jaw, a narrow airway), enlarged tonsils, smoking, and a family history of the condition.

The clinical picture can be misleading, leading to significant underdiagnosis in certain groups. The textbook image — a loudly snoring, overweight man whose partner notices breathing pauses — describes only part of the patient population. Women with OSA more often report atypical symptoms: insomnia, fatigue, low mood, or morning headaches, rather than obvious daytime sleepiness, which frequently leads to misdiagnosis as depression or primary insomnia instead of sleep apnea. Central sleep apnea can be even harder to recognize clinically, since snoring may be minimal or absent, and the dominant symptom is often nighttime breathlessness or an unsettling, irregular breathing pattern — typically Cheyne-Stokes breathing in patients with heart failure. There's also a genuine gray zone of severity — a patient with a borderline-mild apnea index but pronounced daytime symptoms may benefit more from treatment than a patient with a formally moderate index but no symptoms, which shows why the raw number of events per hour should never be the sole basis for a treatment decision.

A common misconception equates sleep apnea with snoring alone — snoring is a very common but nonspecific symptom, occurring in many people without any apnea episodes, while a portion of patients with significant CSA don't snore at all. Another misunderstanding is treating CPAP as the sole, universal treatment for every case of sleep apnea — in reality, the choice of therapy depends on the type and severity of the disorder and its underlying cause, and CSA treatment focuses primarily on the underlying disease, not the breathing symptom itself.

Diagnostically, polysomnography (PSG) performed in a sleep laboratory remains the gold standard, simultaneously recording airflow, chest and abdominal respiratory effort, blood oxygen saturation, brain activity (EEG), and other parameters — it's specifically the recording of respiratory effort that distinguishes an obstructive episode (effort present, airway blocked) from a central one (no effort, no signal from the brain). In adults with a high clinical probability of uncomplicated OSA and no significant comorbidities, home sleep apnea testing (HSAT) is a fully accepted, simpler alternative, recommended by American Academy of Sleep Medicine guidelines.

Obstructive and central sleep apnea, despite sharing a name and a partly overlapping clinical picture, are two different disorders requiring different diagnostic and therapeutic approaches. Understanding this distinction — mechanical obstruction on one hand, instability of the brain's breathing control on the other — is the starting point for proper diagnosis, and effective treatment almost always requires combining an intervention targeting the breathing symptom itself with addressing its underlying drivers, from body weight to cardiovascular disease.